JKMS

Original Article Immunology, Allergic Disorders & Rheumatology

Check for updates

OPEN ACCESS

Received: Nov 17, 2021 Accepted: Dec 1, 2021 Published online: Jan 10, 2022

Address for Correspondence:

Jeong Hee Kim, MD, PhD Department of Pediatrics, Inha University Hospital, 27 Inhang-ro, Jung-gu, Incheon 22332, Korea. Email: kimjhmd@inha.ac.kr

© 2022 The Korean Academy of Medical Sciences.

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https:// creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

ORCID iDs

You Hoon Jeon 问 https://orcid.org/0000-0002-8164-7580 Kangmo Ahn 厄 https://orcid.org/0000-0001-7751-9829 Jihyun Kim 问 https://orcid.org/0000-0001-8493-2881 Meeyong Shin 问 https://orcid.org/0000-0003-3699-8741 Soo-Jong Hong 厄 https://orcid.org/0000-0003-1409-2113 So-Yeon Lee 厄 https://orcid.org/0000-0002-2499-0702 Bok Yang Pyun 🕩 https://orcid.org/0000-0002-6375-9394 Taek Ki Min 问 https://orcid.org/0000-0002-5078-5622

Clinical Characteristics of Atopic Dermatitis in Korean School-Aged Children and Adolescents According to Onset Age and Severity

You Hoon Jeon (b, ¹ Kangmo Ahn (b, ² Jihyun Kim (b, ² Meeyong Shin (b, ³ Soo-Jong Hong (b, ⁴ So-Yeon Lee (b, ⁴ Bok Yang Pyun (b, ⁵ Taek Ki Min (b, ⁵ Minyoung Jung (b, ⁶ Jeongmin Lee (b, ⁷ Tae Won Song (b, ⁸ Hye-Young Kim (b, ⁹ Sooyoung Lee (b, ¹⁰ Kyunguk Jeong (b, ¹⁰ Yoonha Hwang (b, ¹¹ Minji Kim (b, ¹² Yong Ju Lee (b, ¹³ Min Jung Kim (b, ¹³ Ji Young Lee (b, ¹⁴ Hye Yung Yum (b, ¹⁵ Gwang Cheon Jang (b, ¹⁶ Young A Park (b, ¹⁷ Jeong Hee Kim (b) ¹⁸ and on behalf of the Food Allergy and Atopic Dermatitis (FAAD) Study Group in the Korean Academy of Pediatric Allergy and Respiratory Disease

¹Department of Pediatrics, Hallym University, Dongtan Sacred Heart Hospital, Hwaseong, Korea ²Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea ³Department of Pediatrics, Soonchunhyang University Bucheon Hospital, Soonchunhyang University College of Medicine, Bucheon, Korea

⁴Department of Pediatrics, Childhood Asthma Atopy Center, Humidifier Disinfectant Health Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea

⁵Department of Pediatrics, Soonchunhyang University Seoul Hospital, Soonchunhyang University College of Medicine, Seoul, Korea

⁶Department of Pediatrics, Kosin University Gospel Hospital, Kosin University School of Medicine, Busan, Korea ⁷Department of Pediatrics, Yonsei University Wonju College of Medicine, Wonju, Korea

⁸Department of Pediatrics, Ilsan Paik Hospital, Inje University College of Medicine, Goyang, Korea ⁹Department of Pediatrics, Medical Research Institute, Pusan National University School of Medicine, Pusan

- National University Hospital, Busan, Korea
- ¹⁰Department of Pediatrics, Ajou University School of Medicine, Suwon, Korea
- "Department of Pediatrics, Busan St. Mary's Hospital, Busan, Korea

¹²Department of Pediatrics, Chungnam National University Sejong Hospital, Chungnam National University College of Medicine, Sejong, Korea

¹³Department of Pediatrics, Yongin Severance Hospital, Yonsei University College of Medicine, Yongin, Korea
 ¹⁴Department of Pediatrics, Hallym University Chuncheon Sacred Heart Hospital, Chuncheon, Korea
 ¹⁵Department of Pediatrics, Seoul Medical Center, Seoul, Korea

¹⁶Department of Pediatrics, National Health Insurance Service Ilsan Hospital, Goyang, Korea
 ¹⁷Department of Pediatrics, CHA Ilsan Hospital, CHA University School of Medicine, Goyang, Korea
 ¹⁸Department of Pediatrics, Inha University Hospital, College of Medicine, Inha University, Incheon, Korea

ABSTRACT

Background: Atopic dermatitis (AD) is a heterogeneous disease with different age of onset, disease course, clinical symptoms, severity, and risk of comorbidity. The characteristics of children with AD also vary by age or country. However, little is known about the clinical characteristics of AD in Korean school-aged children and adolescents. Furthermore, there are few studies on phenotypic differences according to onset age. This study aimed to explore the clinical characteristics and phenotypes according to onset age and severity of AD in children and adolescents in Korea.

Methods: AD patients aged 6–18 years who presented to 18 hospitals nationwide were surveyed. The patients were examined for disease severity by pediatric allergy specialists, and data on history of other allergic diseases, familial allergy history, onset age, trigger factors, lesion sites,

Minyoung Jung 🔟 https://orcid.org/0000-0003-2851-9480 Jeongmin Lee 厄 https://orcid.org/0000-0002-1672-7445 Tae Won Song 🕩 https://orcid.org/0000-0001-6443-5749 Hye-Young Kim 问 https://orcid.org/0000-0001-7125-8840 Sooyoung Lee https://orcid.org/0000-0003-1734-4101 Kyunguk Jeong 厄 https://orcid.org/0000-0002-1261-4507 Yoonha Hwang 🝺 https://orcid.org/0000-0002-6508-8168 Minii Kim 匝 https://orcid.org/0000-0001-5588-5414 Yong Ju Lee 厄 https://orcid.org/0000-0002-0796-2558 Min Jung Kim 问 https://orcid.org/0000-0002-5634-9709 Ji Young Lee 厄 https://orcid.org/0000-0002-2260-9939 Hye Yung Yum 🕩 https://orcid.org/0000-0002-3997-4094 Gwang Cheon Jang 🕩 https://orcid.org/0000-0002-2423-9951 Young A Park 问 https://orcid.org/0000-0001-6531-8739 Jeong Hee Kim 🕩 https://orcid.org/0000-0002-7054-8552

Disclosure

The authors have no potential conflicts of interest to disclose.

Author Contributions

Conceptualization: Kim JH. Data curation: Jeon YH. Formal analysis: Jeon YH, Lee S, Jeong K. Investigation: Ahn K, Kim J, Hwang Y, Kim M, Lee YJ, Kim MJ, Lee JY. Methodology: Shin M, Hong SJ, Lee SY. Software: Pyun BY, Min TK, Jung M, Lee J, Yum HY. Validation: Song TW, Kim HY. Visualization: Jang GC, Park YA. Writing - original draft: Jeon YH. Writing review & editing: Kim JH. treatment history and quality of life were collected. The results of the patient's allergy test were also analyzed. The patients were classified into infancy-onset (< 2 years of age), preschoolonset (2–5 years of age), and childhood-onset (\geq 6 years of age) groups. Study population was analyzed for clinical features according to onset-age groups and severity groups. Results: A total of 258 patients with a mean age of 10.62 ± 3.18 years were included in the study. Infancy-onset group accounted for about 60% of all patients and presented significantly more other allergic diseases, such as allergic rhinitis and asthma (P = 0.002) and P = 0.001, respectively). Food allergy symptoms and diagnoses were highly relevant to both earlier onset and more severe group. Inhalant allergen sensitization was significantly associated with both infancy-onset group and severe group (P = 0.012 and P = 0.024, respectively). A family history of food allergies was significantly associated with infancyonset group (P = 0.036). Severe group was significantly associated with a family history of AD, especially a paternal history of AD (P = 0.048 and P = 0.004, respectively). Facial (periorbital, ear, and cheek) lesions, periauricular fissures, hand/foot eczema, and xerosis were associated with infancy-onset group. The earlier the onset of AD, the poorer the quality of life (P = 0.038). Systemic immunosuppressants were used in only 9.6% of the patients in the severe group.

Conclusion: This study analyzed the clinical features of AD in Korean children and adolescents through a multicenter nationwide study and demonstrated the phenotypic differences according to onset age and severity. Considering the findings that the early-onset group is more severe and accompanied by more systemic allergic diseases, early management should be emphasized in young children and infants.

Keywords: Adolescence; Age of Onset; Phenotype; Dermatitis, Atopic; Childhood; Severity of Illness Index; Symptom Assessment

INTRODUCTION

Atopic dermatitis (AD) in children increases the risk of food allergies, asthma, allergic rhinitis, and other immune-mediated inflammatory diseases, as well as mental health disorders, and impairs not only the patients' but also their family members' quality of life.¹⁻⁴

AD usually begins in infancy and often improves before school age, but may persist or recur after school age. AD is increasingly considered a lifelong illness presented by waxing and waning symptoms. Currently, there has been increase in prevalence of late onset AD. Moreover, recent epidemiological evidences suggest that the prevalence of AD in school-aged children has exceeded that in preschool children.^{5,6} AD is known as a heterogeneous disease that differs in age of onset, disease course, clinical symptoms, symptom severity, and risk of comorbidity.

Since AD has no disease-specific diagnostic test, it can be diagnosed when various clinical findings satisfy diagnostic criteria. However, AD shows different clinical findings according to age, ethnicity, and region. The most widely accepted diagnostic criteria by Hanifin and Rajka,⁷ which consists of 4 major and 23 minor criteria, is quite complex and has limitations of not reflecting the different characteristics of each country. Although there are some studies on AD in infants and preschool children,^{1,8} little is known about the clinical characteristics of AD in children and adolescents in Korea. Furthermore, there are few studies on differences in clinical characteristics according to onset age in children with AD. Therefore, in order to

prepare a diagnostic guideline representing the phenotype of AD in children and adolescents in Korea, it is necessary to investigate on the characteristics of AD. In addition, there were few data on the characteristics of moderate to severe AD in school-aged children and adolescents, which are expected to differ from those of mild AD.

This multicenter study aimed to investigate the phenotype and clinical characteristics according to the onset age and severity of AD in school-aged children and adolescents in Korea.

METHODS

Study participants

The study population consisted of children with AD aged 6–18 years who presented to the pediatric allergy clinics of 18 secondary and tertiary hospitals nationwide. Hanifin and Rajka's diagnostic criteria⁷ were used for the diagnosis of AD. Patients who consented to the use of their data, including detailed medical history, clinical features, severity assessments, and allergy test results, were included in the study.

Case report forms

All interview contents, examination findings, and laboratory test results were recorded in case report forms. Data on birth history, breastfeeding history, accompanying allergic diseases, family history of allergic diseases, age of AD onset, exacerbating factors, skin care status, and treatment history including systemic antibiotics, steroids or immunosuppressants were collected. Pediatric allergy specialists examined the patients, evaluated the symptoms that met Hanifin and Rajka's minor criteria, investigated the AD lesion sites, and determined the disease severity using both the SCORing Atopic Dermatitis (SCORAD) tool and the Eczema Area and Severity Index (EASI). Numerical Rating Scale (NRS) scores for itching and sleep disturbance were recorded separately. The Children's Dermatology Life Quality Index (CDLQI) was also used. The CDLQI is rated on a scale from 0 to 30, with higher scores indicating poorer quality of life.⁹ Moreover, sleep durations were queried.

Allergen sensitization was evaluated using a skin prick test or serum specific immunoglobulin E (ImmunoCAP; ThermoFisher, Uppsala, Sweden) for common allergens (*Dermatophagoides pteronyssinus* [*Der p*], *Dermatophagoides farinae* [*Der f*], birch, alder, oak, mugwort, ragweed, Japanese hop, Bermuda grass, timothy grass, dog epithelium, cat epithelium, *Alternaria* spp., and *Aspergillus* spp.).

Grouping according to onset age and severity

The patients were classified into three groups according to AD onset age. Patients whose symptoms developed under the age of 2 years were assigned to an infancy-onset group. Patients with symptoms appearing between the ages of two and five years were included in a preschool-onset group. Patients whose symptoms first occurred after the age of six years were assigned to a childhood-onset group.

The patients were also divided into groups according to disease severity. Patients with a SCORAD of less than 25 were included in a mild AD group. Patients with a score between 25 and 50 were assigned to a moderate AD group. Patients with a higher score than 50 were included in a severe AD group.

Statistical analysis

To describe the basic characteristics of the patients, continuous variables were summarized as means and standard deviations, and categorical variables were expressed as frequencies and percentages. ANOVA or linear-by-linear association was used to compare severity, presence or absence of other allergic diseases, family history of allergic diseases, and test findings between the groups. A *P* value of < 0.05 was considered statistically significant. All analyses were performed using SPSS version 26.0 (IBM, Armonk, NY, USA).

Ethics statement

The study protocol was approved by the Institutional Review Boards of Hallym University Dongtan Sacred Heart Hospital (approval No. 2019-12-002) and each participating hospital. Written informed consent was obtained from all patients and their parents at the time of recruitment.

RESULTS

Patients' demographic characteristics and onset age

A total of 258 patients with a mean age of 10.6 years were included in the study. Children aged 6-11 years accounted for 62% (160/258), and adolescents aged 12 years or older accounted for 38% (98/258). The median age of AD onset was 12.5 months, and the median duration of the disease was 8 years. The infancy-onset group accounted for 58.5%, the preschool-onset group accounted for 31.8%, and the childhood-onset group accounted for 15.5% (**Table 1**). Among all patients, 87.6% were breastfed, and 59.7% were breastfed for more than six months. Of all patients, 39.1% were weaned late, after six months of age.

Comorbid allergic diseases and family history of allergic diseases

Among the concomitant allergic diseases, allergic rhinitis was the most common (67.8%), followed by food allergy (36.8%). Thirty-five percent of the patients were exposed to dogs, 17% to cats, and 27% indirectly to smoking. Seventy-eight percent of the patients had a

Characteristics	Values
Sex (male/female)	151 (58.5)/107 (41.5)
Age, yr	10.62 ± 3.18
6-8	79 (30.6)
9-11	81 (31.4)
12-14	63 (24.4)
15-18	35 (13.6)
Onset age, mon	12.50 (3.38-48.00)
Duration of the condition, yr	8.00 (5.00-11.40)
Onset age group, yr	
< 2	136 (58.5)
2-5	82 (31.8)
6-13	40 (15.5)
≥ 1 4	0 (0)
Mode of delivery	
Normal spontaneous vaginal delivery	174 (67.4)
Cesarean section	79 (30.6)
Premature birth	7 (2.7)
Feeding type	
Breast milk only	107 (41.5)
Formula only	30 (11.6)
Mixed	119 (46.1)

Table 1. Demographic characteristics of the study population (N = 258)

Values are presented as number (%) or mean \pm SD or median (IQR).

Variables	Values	
Comorbid allergic diseases		
Asthma	44 (17.1)	
Allergic rhinitis	175 (67.8)	
Allergic conjunctivitis	83 (32.1)	
Food allergy	95 (36.8)	
Chronic urticaria	21 (8.2)	
Drug allergy	9 (3.5)	
Exposure to risk factors		
Dog	91 (35.3)	
Cat	44 (17.1)	
Smoking	71 (27.5)	
Family history of allergy		
Positive family history	201 (77.9)	
Atopic dermatitis	90 (34.9)	
Asthma	16 (6.2)	
Allergic rhinitis	168 (65.1)	
Food allergy	49 (19.0)	

 Table 2. Clinical characteristics of the study population (N = 258)

Values are presented as number (%).

family history of at least one allergic disease; allergic rhinitis was the most common (65.1%), followed by AD (35%) (**Table 2**).

Disease severity

Severe AD group accounted for 40.3% according to SCORAD and 27.5% according to the EASI. The mean subjective NRS scores were 5.8 for itching and 4.3 for sleep disturbance. The average CDLQI score was 8.8, and the mean sleep duration was 8.3 hours (**Table 3**).

Comparison of patients according to onset age

Severe AD with SCORAD of 50 or more was 44.9% in the infancy-onset group and 32.5% in the childhood-onset group. When the severity was divided by EASI, it was 28.7% in the infancy-onset group and 22.5% in the childhood-onset group. The SCORAD and EASI scores tended to be higher in the earlier onset groups than in the late onset group. However, the differences

Table 3. Disease severity and laboratory fi	ndings of the study population (N = 258)
---	--

Variables	Values		Values	
Atopic dermatitis severity				
SCORAD				
Mild (< 25)	51 (19.8)			
Moderate (25-50)	103 (39.9)			
Severe (> 50)	104 (40.3)			
EASI				
Mild (≤ 7.0)	74 (28.7)			
Moderate (7.1–21.0)	99 (38.4)			
Severe (≥ 21.1)	71 (27.5)			
NRS (0-10)				
Itching	5.76 ± 2.08			
Sleep disturbance	4.28 ± 2.81			
CDLQI (0-30)	8.79 ± 5.96			
Sleep hours	8.32 ± 1.32			
Eosinophilia	98/162 (60.5)			
25(OH)D3 (ng/mL)	19.88 ± 18.17			
Total IgE (kU/L)	$1,987.13 \pm 5,945.82$			

Values are presented as number (%) or mean \pm SD.

SCORAD = SCORing Atopic Dermatitis, EASI = Eczema Area and Severity Index, NRS = Numerical Rating Scale, CDLQI = Children's Dermatology Life Quality Index, IgE = immunoglobulin E.

between the groups were not statistically significant (P = 0.054, and P = 0.073, respectively). Food allergy symptoms reported by parents were significantly more common in the infancyonset group (58.1%) than in the preschool-onset (36.6%) and childhood-onset groups (17.5%; P < 0.001). Symptoms of asthma were also significantly more common in the infancy-onset group (34.6%) than in preschool-onset (18.3%) and childhood-onset groups (5.0%; P < 0.001). Doctor confirmed food allergy, asthma, allergic rhinitis, and allergic conjunctivitis diagnoses were also significantly more common in the infancy-onset group (food allergy, asthma, allergic rhinitis: P < 0.001; allergic conjunctivitis: P = 0.020). In groups with younger onset age, there was a tendency to have a family history of food allergies. (P = 0.036).

Among Hanifin and Rajka's minor criteria, xerosis was significantly more frequent in the infancy-onset group than in the other two groups. The earlier the onset age group, the more frequent the facial lesions, including periorbital, cheek, and ear lesions (P = 0.027, P = 0.007, and P = 0.037, respectively). Periauricular fissures were also very frequent in the infancy-onset group. In many children in the infancy-onset group, AD was aggravated by changes in temperature and humidity.

The rates of *Der f* sensitization were 72.8% in the infancy-onset group, 67.1% in the preschool-onset group, and 60.0% in the childhood-onset group. The rate of house dust mite sensitization was higher at younger ages (P = 0.004). Although there were lacking in data because not all patients were tested for all allergens, birch, oak, and weed pollen sensitization showed higher rates in the younger onset age groups. The rates of sensitization to one or more inhalant allergens were statistically significant; 82.4% in the infancy-onset group, 78.0% in the preschool-onset group, and 70.0% in the childhood-onset group (P = 0.012).

In terms of quality of life, the lower the onset age, the higher the CDLQI score and, therefore, the poorer the quality of life (P = 0.038). The use of systemic antibiotics due to AD was also most common (22.1%) in the infancy-onset group (P = 0.048). **Table 4** summarizes the comparison of the characteristics of AD between the three onset age groups.

Comparison of patients according to disease severity

According to SCORAD, patients aged 12 years or older tended to have more severe AD than patients aged 6–11 years. Over 50% of patients aged 12 years or older had severe AD.

The severity of AD did not differ significantly between patients with an onset under the age of two years, patients with an onset between the ages of two and five years, and patients with an onset after the age of six years. However, the difference was statistically significant when the onset age was divided into four groups: less than six months, between six months and one year, between two and five years, and six and over six years. The earlier the onset age, the more severe the condition (P = 0.018). Food allergy symptoms and diagnoses were significantly more common in severe AD patients (P = 0.005 and P = 0.003, respectively). Severe AD was significantly associated with a family history of AD (P = 0.048), especially a paternal history (P = 0.004). Moreover, severe AD was significantly exacerbated by stress or emotional changes (P < 0.001). The severity of the condition also significantly correlated with eosinophilia (P = 0.048).

The rates of *Der p*, dog epithelium, cat epithelium, Japanese hop, and weed mix sensitization were significantly higher in the severe AD group than in the mild and moderate AD groups (P = 0.017, P = 0.000, P = 0.038, P = 0.030, and P = 0.022, respectively). Overall, AD severity significantly correlated with inhalant allergen sensitization (P = 0.024). Food allergen

Table 4. Co	omparison of	patient	characteristics	according t	to onset ag	e
-------------	--------------	---------	-----------------	-------------	-------------	---

Variables	Missing values	Infancy onset group (n = 136)	Preschool-age onset group (n = 82)	Childhood onset group (n = 40)	P value	
Severe AD	·					
SCORAD > 50	1	61 (44.9)	30 (36.6)	13 (32.5)	0.054	
EASI ≥ 21.1	14	39 (28.7)	23 (28.0)	9 (22.5)	0.073	
Allergic symptoms						
Food allergy	17	79 (58.1)	30 (36.6)	7 (17.5)	< 0.001***	
Asthma	11	47 (34.6)	15 (18.3)	2 (5.0)	< 0.001***	
Diagnosis of other allergic diseases						
Food allergy	19	65 (47.8)	23 (28.0)	7 (17.5)	< 0.001***	
Asthma	22	34 (25.0)	8 (9.8)	2 (5.0)	0.001**	
Allergic rhinitis	7	104 (76.5)	49 (59.8)	22 (55.0)	0.002**	
Allergic conjunctivitis	25	54 (39.7)	18 (22.0)	11 (27.5)	0.020*	
Family history of allergic diseases						
Food allergy	11	31 (22.8)	15 (18.3)	3 (7.5)	0.036*	
Atopic dermatitis	12	50 (36.8)	31 (37.8)	9 (22.5)	0.191	
Minor criteria						
Xerosis	30	98 (72.1)	52 (63.4)	27 (67.5)	0.040*	
Immediate skin reaction	31	35 (25.7)	13 (15.9)	6 (15.0)	0.034*	
Hand/foot eczema	31	48 (35.3)	24 (29.3)	9 (22.5)	0.046*	
Food intolerance	31	34 (25.0)	16 (19.5)	2 (5.0)	0.003**	
Nipple eczema	31	11 (8.1)	4 (4.9)	3 (7.5)	0.841	
Periauricular fissure	30	31 (22.8)	16 (19.5)	2 (5.0)	0.010*	
Lesion site						
Periorbital	5	77 (56.6)	45 (54.9)	14 (35.0)	0.027*	
Cheek	5	54 (39.7)	20 (24.4)	8 (20.0)	0.007**	
Ear	5	68 (50.0)	33 (40.2)	11 (27.5)	0.037*	
Aggravation by changes in temperature and humidity	7	114 (83.8)	59 (72.0)	24 (60.0)	0.001**	
Allergen sensitization						
Der f	43	99 (72.8)	55 (67.1)	24 (60.0)	0.004**	
Birch	119	43 (31.6)	16 (19.5)	8 (20.0)	0.025*	
Oak	161	29 (21.3)	6 (7.3)	6 (15.0)	0.049*	
Weed mix	195	14 (10.3)	3 (3.7)	1 (2.5)	0.013*	
Inhalant allergen	31	112 (82.4)	64 (78.0)	28 (70.0)	0.012*	
Food allergen	111	54 (39.7)	23 (28.0)	10 (25.0)	0.073	
CDLQI (0-30)	28	9.60 ± 6.28	8.38 ± 5.45	6.86 ± 5.42	0.038*	
Treatment history						
Systemic steroids	11	25 (18.4)	14 (17.1)	2 (5.0)	0.075	
Systemic antibiotics	11	30 (22.1)	15 (18.3)	3 (7.5)	0.048*	
Systemic immunosuppressants	11	10 (7.4)	3 (3.7)	2 (5.0)	0.387	

Values are presented as number (%), except for CDLQI (mean \pm SD).

Some frequencies do not add up to the total number of cases because of missing values. Statistically significant difference (P < 0.05, *P < 0.01, **P < 0.001). AD = atopic dermatitis, SCORAD = SCORing Atopic Dermatitis, EASI = Eczema Area and Severity Index, *Der f* = *Dermatophagoides farinae*, CDLQI = Children's Dermatology Life Quality Index.

> sensitization was also significantly more common in the severe AD group (P = 0.041). Patients with severe AD used more systemic steroids, immunosuppressants, and antibiotics. As shown in Fig. 1, systemic antibiotics were used by 29.8%, systemic steroids were used by



Fig. 1. Systemic treatments used for severe atopic dermatitis in Korean school-aged children and adolescents.

Variables	Missing values	Mild AD (n = 51)	Moderate AD (n = 103)	Severe AD (n = 104)	P value
Age of ≥ 12 yr	1	15 (29.4)	33 (32.0)	49 (47.1)	0.019*
Onset age group					
< 2 yr ^a	1	21 (41.2)	53 (51.5)	61 (58.7)	0.054
< 6 mon ^b	1	8 (15.7)	29 (28.2)	36 (34.6)	0.018*
Food allergy symptoms	18	13 (25.5)	46 (44.7)	57 (54.8)	0.005**
Food allergy diagnosis	20	11 (21.6)	38 (36.9)	46 (44.2)	0.003**
Family history of AD					
Paternal	13	2 (3.9)	12 (11.7)	20 (19.2)	0.004**
Family	13	12 (23.5)	38 (36.9)	40 (38.5)	0.048*
Aggravation due to stress	7	6 (11.8)	40 (38.8)	44 (42.3)	< 0.001***
Eosinophilia	96	11 (21.6)	41 (39.8)	46 (44.2)	0.048*
Allergen sensitization					
Der p	60	31 (60.8)	64 (62.1)	67 (65.0)	0.017*
Der f	44	34 (66.7)	71 (68.9)	72 (69.2)	0.115
Dog epithelium	74	9 (17.6)	25 (24.3)	45 (43.3)	< 0.001***
Cat epithelium	101	9 (17.6)	18 (17.5)	29 (27.9)	0.038*
Japanese hop	176	2 (3.9)	10 (9.7)	19 (18.3)	0.030*
Weed mix	195	2 (3.9)	4 (3.9)	12 (11.5)	0.022*
Inhalant allergen	32	36 (70.6)	82 (79.6)	85 (81.7)	0.024*
Food allergen	111	16 (31.4)	35 (34.0)	36 (34.6)	0.041*
Treatment history					
Systemic steroids	12	3 (5.9)	14 (13.6)	23 (22.1)	0.013*
Systemic immunosuppressants	12	0 (0.0)	5 (4.9)	10 (9.6)	0.020*
Systemic antibiotics	12	1 (2.0)	16 (15.5)	31 (29.8)	< 0.001***

Values are presented as number (%), except for CDLQI (mean ± SD). Some frequencies do not add up to the total number of cases because of missing values. Mild AD: SCORAD < 25; Moderate AD: SCORAD 25–50; Severe AD: SCORAD > 50.

AD = atopic dermatitis, SCORAD = SCORing Atopic Dermatitis, Der p = Dermatophagoides pteronyssinus, Der f = Dermatophagoides farinae, CDLQI = Children's Dermatology Life Quality Index.

^aOnset age group divided into < 2 years, 2–5 years, and \geq 6 years; ^bonset age group divided into < 6 months, 6 months–1 years, 2–5 years, and \geq 6 years. Statistically significant difference (**P* < 0.05, ***P* < 0.001, ****P* < 0.001).

22.1%, and systemic immunosuppressants were used by 9.6% of severe AD patients. The patient characteristics according to AD severity are summarized in **Table 5**.

DISCUSSION

This is the first nationwide multicenter study to investigate phenotypes and characteristics of AD according to onset of age and severity in school-aged children and adolescents in Korea. This study is meaningful in that it analyzed the characteristics of patients who persisted AD until childhood or adolescent or who developed AD at a later age, rather than transient cases who improved AD before the age of 6 years. The limitation of this study is that there may be a selection bias in enrolling more severe patients because patients who visited secondary or tertiary hospitals were registered. However, the main goal of this study was not to analyze the characteristics and phenotype of all pediatric AD patients, but to analyze the characteristics and treatment status of early-onset group and severe group among school-aged children and adolescents with AD after the age of 6.

This study demonstrated that the infancy-onset AD is more likely to have food allergies, asthma symptoms and other allergic diseases, simultaneously. Since this was a cross-sectional study, it cannot explain a direct causal relationship, however, it suggests that the infancy-onset AD is a phenotype associated with an allergic march. In addition, the patients with infancy-onset AD had a higher family history of food allergies than those in other onset AD groups.

Depending on the age of onset, the AD phenotype can be classified into very early onset, occurring between the ages of 3 months and 2 years; early onset, between the ages of 2 and 6 years; childhood onset, between the ages of 6 and 14 years; adolescent onset, between the ages of 14 and 18 years; adult onset, between the ages of 20 and 60 years; and very late onset, after the age of 60 years. Very early onset accounts for 60–80% of all AD cases, and about 60% of them disappear by age of 2 years and 40% continue beyond age of 2 years, leading to an allergic march associated with allergic rhinitis and/or asthma. Early-onset AD is thought to be a risk factor for chronic diseases. Childhood-onset (6–14 years of age) and adolescent-onset (14–18 years of age) AD has been less studied.¹⁰

Birth cohort studies have demonstrated a link between early-onset AD and school-age asthma and allergic rhinitis.^{11,12} In a cohort study following more than 3,000 infants for 5 vears, children with eczema were 3.07 times more likely to develop asthma than children without eczema. The probability of developing asthma and allergic rhinitis increased with moderate to severe eczema (aOR 3.56 and 3.87, respectively), early-onset eczema (aOR 3.44 and 4.05, respectively), and persistent eczema (aOR 5.16 and 4.00, respectively). Another study showed that a family history of allergic diseases increased the risk of respiratory allergy in AD patients.¹² In our study, a family history of food allergies was associated with infancyonset AD, and a family history of AD was associated with severe AD. A 7-year follow-up study found that early-onset and persistent AD was associated with an increased risk of other atopic diseases and food allergen and aeroallergen sensitization.¹³ Another study on the relationship between allergen sensitization and allergic march in AD patients reported that AD without sensitization was not associated with an increased risk of asthma after the age of 3 (RR 0.46), whereas AD with sensitization increased the risk of asthma by more than 7 times (RR 7.04).^{14,15} That study suggested that in AD, sensitization occurs through the skin, resulting in food allergies, which can lead to an allergic march that develops into respiratory allergies, such as asthma and allergic rhinitis. There is growing evidence of the importance of allergic sensitization through the skin.¹⁶ In children with AD, not only food allergens but also inhalant allergens can be sensitized through the skin, suggesting a link to allergic march.¹⁶⁻²⁰ In our study, food allergen sensitization was associated with more severe but not earlier onset AD, whereas inhalant allergen sensitization was significantly associated with both ADs. This is consistent with a study on children from the Copenhagen Prospective Studies on Asthma in Childhood, which found that early-onset AD and severity were associated with the development of aeroallergen sensitization during childhood.²¹ In a previous study, patients with early-onset and persistent AD often had high SCORAD scores at baseline, food allergen sensitization, and a family history of asthma, while FLG mutations were irrelevant.²² Recent evidence suggests that early-onset AD is a significant risk factor for the transition to other allergic diseases and that clinical characteristics such as onset age, severity, and family history may be more important for prognosis than genetic tests.^{8,10,11,23,24}

In current study, 87.6% of children with AD had been breastfed, and 59.7% of them had been breastfed for more than six months. Breastfeeding has not shown a significant correlation with a high or low risk of AD, while it has shown a moderate correlation with a lower risk of asthma.²⁵ Late introduction (after six months of age) of solid foods in children of our study was common (39.1%). This may be due to parents' concerns over food allergies in infants with AD.

We investigated the common symptoms according to Hanifin and Rajka's minor criteria and compared the common sites of skin lesions between the onset age groups. Food

intolerance, immediate skin reaction, xerosis, and hand/foot eczema were significantly more common in the infancy-onset group. The earlier the onset, the higher the prevalence of lesions in the facial area, including the cheek, ear and periorbital area. In a study analyzing the differences in AD phenotype according to the age of onset, childhood-onset AD was associated with significantly higher rates of involvement of the anterior neck fold, scalp, face, eyelids, Dennie-Morgan folds, hands, feet, and nipples, higher incidence rates of conjunctivitis, cheilitis, pityriasis alba, keratosis pilaris/palmar hyperlinearity/ichthyosis, worsening clinical courses due to emotional or environmental factors, pruritus when sweating, and a stronger tendency toward cutaneous infections compared with adult-onset AD.²⁶ The only characteristic that childhood-onset AD had in common with adult-onset AD was nummular eczema.²⁶ A meta-analysis of age-related AD features found that the pediatric studies reported higher rates of dermatitis in the evelids, auricular area, and ventral aspect of the wrists, exudative eczema, and seborrheic dermatitis-like features compared to the adult studies.²⁷ In an American study on adults, patients over the age of 60 were often affected in the face and scalp, as well as in the buttocks or genitalia. The same study found no differences in lesion distribution according to age of onset (childhood or adulthood).²⁸ However, in a study of adults in Korea, it was found that the flexor surface of arms and legs was more involved in the pre-adult-onset (age < 18 years) group than in the adult-onset group.²⁹ It is noteworthy that in our study, periauricular fissures were particularly common (22.8%) in the infancy onset group and significantly more common than in the childhood onset group (5.0%; P = 0.010). Auricular involvement is known to be common in East Asian populations.²⁷ The prevalence of periauricular eczema in Korean children has been reported to be up to 64.5% and to be associated with Staphylococcus aureus infection.³⁰

AD occurring in the early stages of life is thought to significantly reduce quality of life. In our study, the mean value of CDLQI score in the infancy-onset group (9.60) was significantly higher than that in the childhood-onset group (6.86; P = 0.038). In a Korean study, CDLQI is correlated with AD severity scores as estimated by the SCORAD.³¹ A recent study reported that previous treatment with systemic immunosuppressants, more severe depressive symptoms, itch, impaired sleep, and perceived severity of dermatological symptoms were significant predictors of poor quality of life.³² Patients with AD have been found to exhibit inferior social functioning and mental health scores compared with the general population. Greater disease severity is associated with poorer quality of life and health-related quality of life, especially in children.³³

In terms of systemic treatments, immunosuppressants were used by only 9.6% of the patients in the severe AD group, indicating that systemic immunosuppressants are not commonly used even in children with severe AD in Korea. A recent study found that AD treatment approaches differed considerably between Korean allergy specialists, pediatric allergy specialists, and dermatologists. Pediatric allergy specialists preferred wet wrap therapy and used few systemic immunosuppressants other than cyclosporin.³⁴ This may be because the side effects of these drugs are more worrisome in children. Nevertheless, it is a fact that there are not many treatment options for severe AD in childhood. However, with the recent development of new drugs, the scope of treatment is expected to expand.

Although the present study was not a cohort study, we analyzed the clinical characteristics of AD in detail in children and adolescents aged 6 years and older, for whom there have been few data. Recently, clinical trials and approval of new AD drugs (e.g., dupilumab) have expanded to pediatric patients. Our study makes a significant contribution by analyzing the phenotypes and clinical features and demonstrating the phenotypic differences according to onset age and severity in Korean children and adolescents with AD. The results of current study can be used as important basic data for personalized treatments. This study found that the patients with early-onset AD group were more severe and had more other allergic diseases, highlighting the early management of AD in infants and young children. This study has a 5-year follow-up plan. New treatment plans for each AD phenotype should be developed by further tracking and analyzing the disease courses of these patients.

ACKNOWLEDGMENTS

The authors thank all the members of the Food Allergy and Atopic Dermatitis Study Group (FAAD) under the Korean Academy of Pediatric Allergy and Respiratory Disease (KAPARD) for their assistance in conducting this study.

REFERENCES

- 1. Weidinger S, Novak N. Atopic dermatitis. *Lancet* 2016;387(10023):1109-22. PUBMED | CROSSREF
- Yang G, Seok JK, Kang HC, Cho YY, Lee HS, Lee JY. Skin barrier abnormalities and immune dysfunction in atopic dermatitis. *Int J Mol Sci* 2020;21(8):2867.
 PUBMED L CROSSREF
- Schmidt SA, Olsen M, Schmidt M, Vestergaard C, Langan SM, Deleuran MS, et al. Atopic dermatitis and risk of atrial fibrillation or flutter: A 35-year follow-up study. *J Am Acad Dermatol* 2020;83(6):1616-24.
 PUBMED | CROSSREF
- Jung HJ, Lee DH, Park MY, Ahn J. Cardiovascular comorbidities of atopic dermatitis: using National Health Insurance data in Korea. *Allergy Asthma Clin Immunol* 2021;17(1):94.
 PUBMED | CROSSREF
- Abuabara K, Yu AM, Okhovat JP, Allen IE, Langan SM. The prevalence of atopic dermatitis beyond childhood: a systematic review and meta-analysis of longitudinal studies. *Allergy* 2018;73(3):696-704.
 PUBMED | CROSSREF
- Ha J, Lee SW, Yon DK. Ten-year trends and prevalence of asthma, allergic rhinitis, and atopic dermatitis among the Korean population, 2008–2017. *Clin Exp Pediatr* 2020;63(7):278-83.
 PUBMED | CROSSREF
- 7. Hanifin JM. Diagnostic features of atopic dermatitis. Acta Derm Venereol 1980;92:44-7.
- Roduit C, Frei R, Depner M, Karvonen AM, Renz H, Braun-Fahrländer C, et al. Phenotypes of atopic dermatitis depending on the timing of onset and progression in childhood. *JAMA Pediatr* 2017;171(7):655-62.
 PUBMED | CROSSREF
- Lewis-Jones MS, Finlay AY. The Children's Dermatology Life Quality Index (CDLQI): initial validation and practical use. *Br J Dermatol* 1995;132(6):942-9.
 PUBMED | CROSSREF
- Bieber T, D'Erme AM, Akdis CA, Traidl-Hoffmann C, Lauener R, Schäppi G, et al. Clinical phenotypes and endophenotypes of atopic dermatitis: Where are we, and where should we go? *J Allergy Clin Immunol* 2017;139(4 4S):S58-64.
 PUBMED | CROSSREF
- Saunes M, Øien T, Dotterud CK, Romundstad PR, Storrø O, Holmen TL, et al. Early eczema and the risk of childhood asthma: a prospective, population-based study. *BMC Pediatr* 2012;12(1):168.
 PUBMED | CROSSREF
- von Kobyletzki LB, Bornehag CG, Hasselgren M, Larsson M, Lindström CB, Svensson Å. Eczema in early childhood is strongly associated with the development of asthma and rhinitis in a prospective cohort. *BMC Dermatol* 2012;12(1):11.
 PUBMED | CROSSREF
- Carlsten C, Dimich-Ward H, Ferguson A, Watson W, Rousseau R, Dybuncio A, et al. Atopic dermatitis in a high-risk cohort: natural history, associated allergic outcomes, and risk factors. *Ann Allergy Asthma Immunol* 2013;110(1):24-8.
 PUBMED | CROSSREF

https://jkms.org

- Tran MM, Lefebvre DL, Dharma C, Dai D, Lou WYW, Subbarao P, et al. Predicting the atopic march: Results from the Canadian Healthy Infant Longitudinal Development Study. J Allergy Clin Immunol 2018;141(2):601-7 e8.
- 15. Tran MM, Sears MR. Can the atopic march be predicted? *Ann Allergy Asthma Immunol* 2018;120(2):115-6. PUBMED | CROSSREF
- Brough HA, Nadeau KC, Sindher SB, Alkotob SS, Chan S, Bahnson HT, et al. Epicutaneous sensitization in the development of food allergy: what is the evidence and how can this be prevented? *Allergy* 2020;75(9):2185-205.
 PUBMED | CROSSREF
- Beck LA, Leung DY. Allergen sensitization through the skin induces systemic allergic responses. J Allergy Clin Immunol 2000;106(5 Suppl):S258-63.
- Boralevi F, Hubiche T, Léauté-Labrèze C, Saubusse E, Fayon M, Roul S, et al. Epicutaneous aeroallergen sensitization in atopic dermatitis infants - determining the role of epidermal barrier impairment. *Allergy* 2008;63(2):205-10.
 PUBMED | CROSSREF
- Tham EH, Rajakulendran M, Lee BW, Van Bever HP. Epicutaneous sensitization to food allergens in atopic dermatitis: What do we know? *Pediatr Allergy Immunol* 2020;31(1):7-18.
 PUBMED | CROSSREF
- Deckers J, Sichien D, Plantinga M, Van Moorleghem J, Vanheerswynghels M, Hoste E, et al. Epicutaneous sensitization to house dust mite allergen requires interferon regulatory factor 4-dependent dermal dendritic cells. *J Allergy Clin Immunol* 2017;140(5):1364-1377.e2.
- Schoos AM, Chawes BL, Bønnelykke K, Stokholm J, Rasmussen MA, Bisgaard H. Increasing severity of early-onset atopic dermatitis, but not late-onset, associates with development of aeroallergen sensitization and allergic rhinitis in childhood. *Allergy* 2021;00:1-9.
 PUBMED | CROSSREF
- Zhang Z, Li H, Zhang H, Cheng R, Li M, Huang L, et al. Factors associated with persistence of earlyonset atopic dermatitis up to the age of 12 years: a prospective cohort study in China. *Eur J Dermatol* 2021;31(3):403-8.
 PUBMED | CROSSREF
- 23. Tham EH, Leung DY. Mechanisms by which atopic dermatitis predisposes to food allergy and the atopic march. *Allergy Asthma Immunol Res* 2019;11(1):4-15.
 PUBMED | CROSSREF
- Jun M, Wang HY, Lee S, Choi E, Lee H, Choi EH. Differences in genetic variations between treatable and recalcitrant atopic dermatitis in Korean. *Allergy Asthma Immunol Res* 2018;10(3):244-52.
 PUBMED | CROSSREF
- 25. Güngör D, Nadaud P, LaPergola CC, Dreibelbis C, Wong YP, Terry N, et al. Infant milk-feeding practices and food allergies, allergic rhinitis, atopic dermatitis, and asthma throughout the life span: a systematic review. *Am J Clin Nutr* 2019;109(Suppl 7):772S-799S.
 PUBMED | CROSSREF
- Silverberg JI, Vakharia PP, Chopra R, Sacotte R, Patel N, Immaneni S, et al. Phenotypical differences of childhood- and adult-onset atopic dermatitis. *J Allergy Clin Immunol Pract* 2018;6(4):1306-12.
 PUBMED | CROSSREF
- Yew YW, Thyssen JP, Silverberg JI. A systematic review and meta-analysis of the regional and age-related differences in atopic dermatitis clinical characteristics. *J Am Acad Dermatol* 2019;80(2):390-401.
 PUBMED | CROSSREF
- Silverberg JI, Margolis DJ, Boguniewicz M, Fonacier L, Grayson MH, Ong PY, et al. Distribution of atopic dermatitis lesions in United States adults. *J Eur Acad Dermatol Venereol* 2019;33(7):1341-8.
 PUBMED | CROSSREF
- Son JH, Chung BY, Kim HO, Park CW. Clinical features of atopic dermatitis in adults are different according to onset. *J Korean Med Sci* 2017;32(8):1360-6.
 PUBMED | CROSSREF
- Kim KH, Hwang JH, Park KC. Periauricular eczematization in childhood atopic dermatitis. *Pediatr Dermatol* 1996;13(4):278-80.
 PUBMED | CROSSREF
- Kim DH, Li K, Seo SJ, Jo SJ, Yim HW, Kim CM, et al. Quality of life and disease severity are correlated in patients with atopic dermatitis. *J Korean Med Sci* 2012;27(11):1327-32.
 PUBMED | CROSSREF

- 32. Ferrucci SM, Tavecchio S, Angileri L, Surace T, Berti E, Buoli M. Factors associated with affective symptoms and quality of life in patients with atopic dermatitis. *Acta Derm Venereol* 2021;101(11):adv00590. PUBMED | CROSSREF
- Maksimović N, Janković S, Marinković J, Sekulović LK, Zivković Z, Spirić VT. Health-related quality of life in patients with atopic dermatitis. *J Dermatol* 2012;39(1):42-7.
 PUBMED | CROSSREF
- Yum HY, Kim HH, Kim HJ, Kim WK, Lee SY, Li K, et al. Current management of moderate-to-severe atopic dermatitis: a survey of allergists, pediatric allergists and dermatologists in Korea. *Allergy Asthma Immunol Res* 2018;10(3):253-9.
 PUBMED | CROSSREF